- Home
- PYXS vs RVPH Comparison
PYXS vs RVPH Comparison
Compare PYXS & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYXS
- RVPH
- Stock Information
- Founded
- PYXS 2018
- RVPH 2006
- Country
- PYXS United States
- RVPH United States
- Employees
- PYXS N/A
- RVPH N/A
- Industry
- PYXS Biotechnology: Pharmaceutical Preparations
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- PYXS Health Care
- RVPH Health Care
- Exchange
- PYXS Nasdaq
- RVPH Nasdaq
- Market Cap
- PYXS 101.1M
- RVPH 87.6M
- IPO Year
- PYXS 2021
- RVPH N/A
- Fundamental
- Price
- PYXS $1.50
- RVPH $1.77
- Analyst Decision
- PYXS Strong Buy
- RVPH Strong Buy
- Analyst Count
- PYXS 8
- RVPH 5
- Target Price
- PYXS $9.43
- RVPH $12.00
- AVG Volume (30 Days)
- PYXS 817.5K
- RVPH 3.3M
- Earning Date
- PYXS 11-12-2024
- RVPH 11-14-2024
- Dividend Yield
- PYXS N/A
- RVPH N/A
- EPS Growth
- PYXS N/A
- RVPH N/A
- EPS
- PYXS N/A
- RVPH N/A
- Revenue
- PYXS $16,146,000.00
- RVPH N/A
- Revenue This Year
- PYXS N/A
- RVPH N/A
- Revenue Next Year
- PYXS N/A
- RVPH N/A
- P/E Ratio
- PYXS N/A
- RVPH N/A
- Revenue Growth
- PYXS N/A
- RVPH N/A
- 52 Week Low
- PYXS $1.39
- RVPH $0.60
- 52 Week High
- PYXS $6.85
- RVPH $4.83
- Technical
- Relative Strength Index (RSI)
- PYXS 36.16
- RVPH 49.95
- Support Level
- PYXS $1.39
- RVPH $1.56
- Resistance Level
- PYXS $1.82
- RVPH $1.86
- Average True Range (ATR)
- PYXS 0.10
- RVPH 0.25
- MACD
- PYXS 0.03
- RVPH -0.03
- Stochastic Oscillator
- PYXS 25.58
- RVPH 34.43
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.